MTX240 / Otsuka, Biodexa Pharma - LARVOL DELTA

The Role of PDE3A in Cancer. (PubMed, ACS Omega) - "PDE3A plays a pivotal role in tumorigenesis and cancer progression, with aberrant expression strongly associated with tumor proliferation, metastasis, and resistance to chemotherapy. As a therapeutic target, PDE3A holds significant potential. The development of PDE3A inhibitors or molecular adhesive agents may offer novel treatment strategies, particularly for chemotherapy-resistant tumor types."

Journal • Review • Breast Cancer • Gastrointestinal Stromal Tumor • Hepatocellular Cancer • Oncology • Sarcoma • Solid Tumor • Fascin • FSCN1 • METTL3 • MYBL2 • PDE3A

Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer (ACCESS Newswire) - "Enter MTX240, Biodexa's latest developmental treatment, which it recently licensed from Otsuka Pharmaceutical Co., Ltd...In addition, MTX240 has issued Composition of Matter patents extending through 2037...Next step is to manufacture clinical trial supplies of MTX240 and then initiate a Phase 1b/2a study by year-end. The study is expected to be in two parts: a standard dose escalation part to determine a maximum tolerated dose, followed by an extension part. The extension part is likely to enrol patients with TKI-resistant GIST....Biodexa in-licensed exclusive worldwide rights to MTX240 with the exception of Japan rights, which were retained by Otsuka for an undisclosed upfront fee. The deal includes one modest development milestone, low double digit approval milestones and mid single-digit tiered royalties."

Licensing / partnership • New P1/2 trial • Patent • Gastrointestinal Stromal Tumor

Biodexa Announces Exclusive License of Otsuka’s OPB-171775, a potent Phase 1 ready Molecular Glue for GIST (GlobeNewswire) - "The compound also has the potential to be useful in additional indications. In Biodexa’s pipeline, OPB-171775 is to be coded MTX240....Under the terms of the license agreement Biodexa has the exclusive rights to develop and commercialize MTX240 globally with the exception of Japan where Otsuka retains its rights. The agreement includes an upfront fee and additional development and regulatory milestones. In addition, tiered royalties in the mid-single digit range are payable on net sales of MTX240."

Licensing / partnership • Gastrointestinal Stromal Tumor

Novel Mechanism of Action Shown to be Effective in TKI Resistant PDX Models (GlobeNewswire) - "By triggering cell death through this alternative pathway, MTX240 is designed to overcome the resistance mechanisms that render TKI-resistant GISTs refractory to conventional kinase inhibitors....In patient derived xenograft (PDX) mice, MTX240 has shown dose-dependent anti-tumor efficacy in imatinib and sunitinib resistant models irrespective of KIT mutation status as demonstrated by E.O."

Preclinical • Gastrointestinal Stromal Tumor

A PDE3A-SLFN12 Molecular Glue Exhibits Significant Antitumor Activity in TKI-Resistant Gastrointestinal Stromal Tumors. (PubMed, Clin Cancer Res) - "These findings suggest that OPB-171775, with its significant efficacy, could potentially serve as a novel and effective treatment option for advanced GISTs, particularly those resistant to TKIs."

Journal • Stroma • Gastrointestinal Cancer • Gastrointestinal Disorder • Gastrointestinal Stromal Tumor • Oncology • Sarcoma • Targeted Protein Degradation • KIT • PDE3A • PDGFRA • SLFN